2024-10-15 - Analysis Report
##  Johnson & Johnson (JNJ) Stock Analysis Report 

**Company Overview:** Johnson & Johnson is a multinational pharmaceutical, medical device, and consumer packaged goods company. 

**1. Performance vs. S&P 500 (VOO):**

* **Cumulative Return:** JNJ: 34.75%, VOO: 135.82%.
* **Relative Performance:** JNJ is significantly lagging behind VOO, with a cumulative return difference of -101.07%. This places JNJ at the 3.93 percentile of its historical performance relative to VOO, indicating a period of underperformance. 

**2. Recent Price Movement:**

* **Closing Price:** $161.46
* **Moving Averages:** 5-day: $160.36, 20-day: $162.36, 60-day: $161.75.
* **Analysis:**  The stock is currently trading slightly below its 20-day moving average, suggesting a potential short-term downtrend. However, it remains above its 5-day and 60-day moving averages, indicating a more neutral long-term outlook.

**3. Technical Indicators:**

* **RSI:** 41.54 - This suggests that JNJ is currently in a neutral to slightly oversold territory.
* **PPO:** -0.15 -  A negative PPO value indicates that the short-term momentum is weaker than the long-term momentum, potentially suggesting a continuation of the downward trend.
* **Delta_Previous_Relative_Divergence:** -8.37 - This negative value indicates that the stock's recent performance (over the last 20 days) has weakened relative to its historical trend.
* **Expected Return:** 0.0% - Based on the current market conditions, a 5-year expected return for JNJ is expected to be 0%.

**4. Recent Earnings and Outlook:**

| Date      | EPS     | Revenue     |
|----------|---------|-------------|
| 2024-07-25 | 1.95    | 22.45 B$    |
| 2024-05-01 | 1.35    | 21.38 B$    |
| 2024-02-16 | 1.68    | 21.39 B$    |
| 2023-10-27 | 10.32   | 21.35 B$    |
| 2024-02-16 | 10.32   | 21.35 B$    |

* **Analysis:** The latest earnings report for Q2 2024 was released on July 25th, with EPS of $1.95 and revenue of $22.45 Billion. This was slightly higher than analysts' expectations of $1.94 and $22.36 Billion. However, revenue growth slowed down in Q2, which may indicate a challenging market environment.  Further analysis of the company's financial statements and management's comments on the earnings call are needed to understand the full impact of the earnings results.

**5. News and Recent Issues:**

* **Recent Market Outlook:** The market remains volatile, with concerns about inflation, interest rates, and geopolitical instability impacting investor sentiment. JNJ, as a large-cap stock, is likely to be affected by these broader market trends.
* **Analyst Opinions:** While JNJ is considered a well-established company with a strong dividend track record, recent analyst reports have indicated mixed opinions. Some analysts remain optimistic, citing the company's strong brand recognition and diversified business model. Others are concerned about potential headwinds such as increased competition and regulatory scrutiny.
* **Performance Highlights:** JNJ has historically been a strong performer, but recent years have seen a slowdown in growth. The company is facing challenges in its pharmaceutical segment due to patent expirations and generic competition. However, its medical device and consumer health businesses continue to perform well.

**6. Overall Analysis:**

JNJ is a well-established company with a strong brand and diverse revenue streams. However, its recent performance has been underwhelming compared to the broader market, and its growth outlook remains uncertain. The company faces challenges from increased competition, patent expirations, and regulatory scrutiny.  While the stock's technical indicators suggest a potential for short-term weakness, its strong dividend and long-term growth potential still make it an attractive investment for some investors.  Further research and analysis are recommended to determine if JNJ is a suitable addition to a portfolio.

**7. Disclaimer:** This report is for informational purposes only and should not be considered financial advice. 
